Outcomes of patients with low-risk differentiated thyroid cancer with an excellent response to initial therapy
Authors:
- Carlos Garcia-RegalCGCarlos Garcia-Regal
- Jhonatan Quiñones-SilvaJQJhonatan Quiñones-Silva
- Noemi Brox-TorrecillaNBNoemi Brox-Torrecilla
- Alberto Martinez-LorcaAMAlberto Martinez-Lorca
- Ignacio Ruz-CaracuelIgnacio Ruz-Caracuel
- Sonsoles Aso MansoSMSonsoles Aso Manso
- Ana Maria Garcia CanoACAna Maria Garcia Cano
- Marta RosilloMRMarta Rosillo
- Maria Isabel García Gómez MurielMMMaria Isabel García Gómez Muriel
Open Access
- 28 August 2026
- journal article
- Published by Bioscientifica in European Thyroid Journal
- Vol. 15 (5)
Abstract
Objective: Patients with differentiated thyroid carcinoma (DTC) classified as low risk of recurrence and an excellent response to initial treatment should have a particularly low risk of recurrence. Our objective was to assess the recurrence rate in these patients to support follow-up de-escalation. Methods: A multicenter retrospective study was conducted in six Spanish hospitals, including consecutive patients diagnosed with low-risk DTC between 2015 and 2018 with an excellent response to initial therapy. Results: A total of 379 patients were included, with a median follow-up of 6.7 years. Response to therapy at the last follow-up, according to the 2015 ATA/Momesso criteria, was excellent in 349 patients (92.1%), indeterminate in 29 (7.6%), and biochemical incomplete in 1 (0.3%). The overall incidence of indeterminate response was 11.8 events per 1,000 person-years, peaking at year 3 of follow-up and dropping to nearly zero after year 7. PTC and RAI treatment were associated with a lower probability of developing an indeterminate response (P = 0.02 and P = 0.03, respectively). When applying the 2025 ATA criteria, the excellent response rate increased to 95.8% and neither papillary histology nor RAI treatment was significantly associated (P = 0.07 and P = 0.61, respectively). During follow-up, indeterminate/suspicious findings on ultrasound were observed in 39 patients (10.3%). FNA was performed in 20 of these, none of which found recurrence. Conclusions: Recurrences in patients with low risk of recurrence and an excellent response to initial therapy are extremely infrequent. These data support follow-up de-escalation in this population. Significance statement: In this multicenter retrospective study of low-risk DTC patients with an excellent response to initial treatment, no recurrences were observed among 379 patients after a median follow-up of 6.7 years. The overall incidence rate of indeterminate response was 11.8 events per 1,000 person-years, peaking around year 3 after surgery and progressively declining thereafter, approaching zero after year 7. Using the 2025 ATA response-to-therapy criteria, 95.8% of patients maintained an excellent response at the last follow-up, and no variable was associated with the development of an indeterminate response. These findings support follow-up de-escalation.Keywords
This publication has 28 references indexed in Scilit:
- Determinants of physicians’ risk-benefit perceptions of adjuvant radioactive iodine for differentiated thyroid cancerEndocrine, 2026
- Thyroidectomy with or without postoperative radioiodine for patients with low-risk differentiated thyroid cancer in the UK (IoN): a randomised, multicentre, non-inferiority trialThe Lancet, 2025
- Contribution of neck ultrasonography to patient management in patients with differentiated thyroid carcinoma with excellent response to therapyEndocrine, 2024
- Thyroidectomy without radioiodine in patients with low-risk thyroid cancer: 5 years of follow-up of the prospective randomised ESTIMABL2 trialThe Lancet Diabetes & Endocrinology, 2024
- Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trialThe Lancet Diabetes & Endocrinology, 2019
- Dynamic risk stratification in papillary thyroid carcinoma measuring 1 to 4 cmJournal of Surgical Oncology, 2018
- Outcome after ablation in patients with low-risk thyroid cancer (ESTIMABL1): 5-year follow-up results of a randomised, phase 3, equivalence trialThe Lancet Diabetes & Endocrinology, 2018
- Italian consensus on diagnosis and treatment of differentiated thyroid cancer: joint statements of six Italian societiesJournal of Endocrinological Investigation, 2018
- Update on Differentiated Thyroid Cancer StagingEndocrinology and Metabolism Clinics of North America, 2014
- Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines TaskforceThyroid®, 2006